Marina Biotech to Participate in the 7th Annual LD Micro Invitational on June 7

LOS ANGELES, CA / ACCESSWIRE / May 31, 2017 / Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension and cancer, today announced that it will be presenting at the 7th annual LD Micro Invitational on Wednesday, June 7th at 1:30 PM PST / 4:30 PM EST. Joseph Ramelli, Chief Executive Officer, will be giving the presentation and meeting with investors.

“This year, not only do we have a record number of companies making their LD Micro debuts, but a record number of companies presenting for the first time in their company’s history,” stated Chris Lahiji, President of LD Micro. “LD has established itself as the one venue that brings the most influential players from all segments of the market under one roof.”

The conference will be held at the Luxe Sunset Bel Air Hotel and will feature 180 companies in the small / micro-cap space.

View Marina Biotech’s profile here: http://www.ldmicro.com/profile/MRNA

Profiles powered by LD Micro – News Compliments of ACCESSWIRE.

About Marina Biotech

Marina Biotech is a biotechnology company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension, and cancer. Our pipeline includes combination therapies of oligonucleotide-based therapeutics and small molecules. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome). By its merger with IthenaPharma, Marina Biotech recently acquired IT-102/IT-103 – next generation celecoxib – which will be developed together with CEQ508 as a therapeutic enhancer for therapies against FAP and CRC. IT-102/IT-103 are also being developed for the treatment of combined arthritis/ hypertension and treatment of pain requiring high dose of celecoxib. Additional information about Marina Biotech is available at http://www.marinabio.com.

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

Investor Contact

Garth Russell / Allison Soss
KCSA Strategic Communications
Phone: (212) 896-1250 / (212) 896-1267
Email: grussell@kcsa.com / asoss@kcsa.com

SOURCE: Marina Biotech

ReleaseID: 464473